ARS Pharmaceuticals awarded Chief Commercial Officer Margaret Ekins 1,001,738 derivative securities on September 1, 2026. Her ownership after the transaction was 1,001,738 derivative securities, giving investors a precise view of the reported executive holding and the transaction’s resulting position.

Key Highlights

  • Margaret Ekins serves as Chief Commercial Officer of ARS Pharmaceuticals.
  • The transaction took place on September 1, 2026.
  • The reported transaction used SEC code A.

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) awarded Chief Commercial Officer Margaret Ekins 1,001,738 derivative securities. The transaction leaves Ekins with ownership of 1,001,738 derivative securities, matching the amount awarded.

Executive Award Leaves 1,001,738 Securities Owned

Ekins’ transaction was recorded on September 1, 2026, under SEC transaction code A. The award involved derivative securities of ARS Pharmaceuticals. Ekins is identified as the company’s Chief Commercial Officer. Her reported ownership following the transaction stands at 1,001,738 derivative securities. Both figures are 1,001,738, with the first representing the securities awarded and the second representing Ekins’ holdings after the transaction. ARS Pharmaceuticals is listed on Nasdaq under SPRY.